PHARMACOKINETICS (PK) OF FENOFIBRIC ACID AND ROSUVASTATIN IN SUBJECTS WITH MILD TO MODERATE RENAL IMPAIRMENT.

被引：0
|
作者：
Zhu, T. [1 ]
Williams, L. [1 ]
Awni, W. [1 ]
Smith, W. [2 ]
Locke, C. [1 ]
Pradhan, R. [1 ]
机构：
[1] Abbott Labs, Abbott Pk, IL 60064 USA
[2] New Orleans Ctr Clin Res, Knoxville, TN USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] Lubeluzole pharmacokinetics in subjects with mild, moderate and severe renal impairment.
    Burstein, AH
    Lee, PID
    Gajjar, D
    Zhou, H
    Soo, Y
    Pesco-Koplowitz, L
    Hantson, L
    Woestenborghs, R
    Young, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 189 - 189
  • [2] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S87 - S88
  • [3] Pharmacokinetics (PK) of garenoxacin in healthy subjects and in subjects with hepatic impairment.
    Noveck, RJ
    Vargas, R
    Russo, R
    Bello, A
    Gajjar, D
    Grasela, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P79 - P79
  • [4] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Yang, Haijing
    Zhang, Min
    Chen, Yuancheng
    Ren, Hong
    Zhang, Hong
    Yu, Chen
    Lu, Jianda
    You, Li
    Yu, Jicheng
    Liang, Hong
    Xiao, Cuilan
    He, Zishuang
    Wu, Jufang
    Xue, Jun
    Zhang, Jing
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (07) : 1079 - 1086
  • [5] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Haijing Yang
    Min Zhang
    Yuancheng Chen
    Hong Ren
    Hong Zhang
    Chen Yu
    Jianda Lu
    Li You
    Jicheng Yu
    Hong Liang
    Cuilan Xiao
    Zishuang He
    Jufang Wu
    Jun Xue
    Jing Zhang
    European Journal of Clinical Pharmacology, 2022, 78 : 1079 - 1086
  • [6] Bucindolol (B) single dose pharmacokinetics (PK) in subjects with varying degrees of renal impairment.
    Ogunremi, A
    Swan, S
    Gehr, T
    Sica, D
    Sellers, J
    Roberge, P
    Ward, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 158 - 158
  • [7] FTY720 pharmacokinetics in mild to moderate hepatic impairment.
    Kovarik, JM
    Schmouder, RL
    Serra, D
    Wang, Y
    Lasseter, K
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 473 - 473
  • [8] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment.
    Jacobsen, LV
    Popescu, G
    Plum, A
    DIABETOLOGIA, 2002, 45 : A259 - A260
  • [10] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S88 - S88
12345